Shamburg News · 8-K filed Nov 10, 2026, 4:05 PM EST
Capricor Therapeutics Reports Third Quarter 2026 Financial Results and Corporate Update
CAPR · CAPRICOR THERAPEUTICS, INC.
- Earnings
- Materiality: high
Capricor Therapeutics reported a third-quarter 2026 net loss of approximately $42.7 million, or $0.73 per share, compared with a net loss of approximately $24.6 million, or $0.54 per share, a year earlier. The company reported no revenue for the quarter and total operating expenses of approximately $44.7 million. Cash, cash equivalents, restricted cash and marketable securities totaled approximately $198.5 million as of September 30, 2026, and the Deramiocel BLA has a PDUFA target action date of November 22, 2026.
Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001104659-26-125150.
Written from the filing by Shamburg Markets. Figures are as reported by the company.